Condition P07A

Heart failure with left ventricular ejection fraction above 40 percent

Adults with heart failure and LVEF above 40 percent (mildly reduced or preserved).

4 randomized trials; 0 fitted analyses across 7 outcomes.

All outcomes

Each outcome is analyzed per time window and estimand, with doses kept apart (each dose) and pooled (each medicine). Analyses with too few connected trials are shown as descriptive.

Cardiovascular death or heart failure eventsprimary

O40

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Cause specific hazards	Each dose separately	1	2	Descriptive only
longest follow-up	Cause specific hazards	Doses of a drug pooled	1	2	Descriptive only

KCCQ clinical summary score changeprimary

O41

Time window	Estimand	Treatments	Trials	Nodes	Analysis
weeks 36 to 64 (target week 52)	Hypothetical (as if everyone stayed on treatment)	Doses of a drug pooled	1	2	Descriptive only
weeks 36 to 64 (target week 52)	Hypothetical (as if everyone stayed on treatment)	Each dose separately	1	2	Descriptive only
weeks 36 to 64 (target week 52)	Treatment policy	Doses of a drug pooled	1	2	Descriptive only
weeks 36 to 64 (target week 52)	Treatment policy	Each dose separately	1	2	Descriptive only

Heart failure events

O23B

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Cause specific hazards	Doses of a drug pooled	1	2	Descriptive only
longest follow-up	Cause specific hazards	Each dose separately	1	2	Descriptive only

Serious adverse events

O25

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Each dose separately	1	2	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only

Discontinuation due to adverse events

O26

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Each dose separately	1	2	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only

Discontinuation due to gastrointestinal adverse events

O27E

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Each dose separately	1	2	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only

Acute pancreatitis

O29

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only
longest follow-up	Recorded harms	Each dose separately	1	2	Descriptive only